Indefinite Delivery Contract 75F40120D00032

Award Date 9/29/20
Last Date to Order 9/29/25
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery contract to We Pharma, Inc., doing business as WEP Clinical. The single award contract has a potential value of $6M over its period of performance from June 2021 through August 2026. Under the contract, WEP Clinical will provide pharmaceutical products and emergency delivery services to support FDA operations. Task orders issued to date include $240K in products for domestic manufacturing...
The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery contract to Propharma Group, LLC (doing business as Acadeus) with a potential value of $25 million. The contract provides review of Laboratory-Developed Tests and In Vitro Diagnostics Support through March 6, 2027. A $7.736 million firm fixed price delivery order was also awarded for the period of March 2, 2022 through September 6, 2024 in Silver Spring, Maryland. Under this delivery order,...
The Department of Health and Human Services Food and Drug Administration awarded a single award indefinite delivery contract to Core Human Factors, Inc. with a potential value of $10,000,000. The contract aims to procure comparative use human factors studies to assess the impact of differences between the user interfaces of generic drug-device combination products and their reference listed drugs. A firm fixed price delivery order for $1,035,113 was issued against this contract. Core Human...
The Department of Health and Human Services Food and Drug Administration awarded a single-award Indefinite Delivery Contract to Source Healthcare Analytics LLC with a potential value of $45 million. Under the contract, Source Healthcare will provide the FDA access to outpatient prescription and patient level drug utilization data over a five-year period ending in May 2025. Task Order 1 was issued with a firm fixed price value of $20.2 million. Source Healthcare will support the FDA's efforts...
The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded an Indefinite Delivery Contract (IDC) to Research Triangle Institute (RTI International), a non-profit research organization, for the "Economic Studies of FDA Regulations" program. The $9,901,000 multiple-award IDC has a period of performance through September 14, 2024. Under this IDC, RTI has been issued several delivery orders, including: A $0 task order to develop an economic...
The Department of Health and Human Services' Food and Drug Administration (FDA) has awarded an indefinite delivery contract to Eastern Research Group Inc. (ERG), a for-profit Subchapter S Corporation, to provide economic studies and analysis in support of FDA regulatory programs. The $9.9 million multiple award contract, with a period of performance through September 2024, allows the FDA to issue task orders for a variety of economic research and data analysis services. Under this contract,...
The Department of Health and Human Services Food and Drug Administration awarded a single award Blanket Purchase Agreement to Contact Government Services LLC valued at up to $60,000,000 to provide eDiscovery operational support services and technology management. Under the terms of the BPA, the FDA issued an initial task order worth $5,779,831.34 for eDiscovery services with a period of performance from September 2023 through March 2026 in Washington D.C. The BPA and first task order aim to...
The provided information describes a Indefinite Delivery Contract (IDC) awarded by the U.S. Food and Drug Administration (FDA), a civilian federal agency, to the prime contractor Syneos Health Research & Insights LLC. The IDC has a ceiling value of $3,446,837.42 and a period of performance from May 16, 2023 to May 16, 2025. The purpose of the contract is to provide the FDA with "ACCESS TO HEALTHCARE PRACTITIONER PRESCRIBING PRACTICES DATA". This requirement was originally solicited...
The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery, indefinite quantity contract to Koniag Management Solutions LLC with a potential value of $25,000,000. Task orders issued against the contract procure scientific support services including research, laboratory analysis, and subject matter expertise to support the FDA's regulatory, compliance and public health programs. Task orders awarded to Koniag Management Solutions LLC and described in...
The Department of Health and Human Services' Food and Drug Administration (FDA) awarded an Indefinite Delivery Contract (IDC) valued at $45 million to Iqvia Government Solutions Inc., a leading provider of healthcare data, analytics, and related services to federal agencies. The contract enables the FDA to issue task orders for access to outpatient prescription and patient-level drug utilization data to support its regulatory programs and post-market drug safety monitoring initiatives over a...
  • 75F40120D00032
    Indefinite Delivery Contract
  • 8
    Federal Contract Awards

The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery contract to We Pharma, Inc., doing business as WEP Clinical, with a potential value of $9.5 million. The contract has no set-aside designation and is a single-award arrangement to provide currently marketed drug products for FDA research studies from September 2020 through September 2025.

Under this contract, WEP Clinical has received multiple firm fixed price delivery orders to supply pharmaceuticals to the FDA's offices in Silver Spring, Maryland; St. Louis, Missouri; and Morrisville, North Carolina. Delivery orders range in value from $100,000 to $500,000 with periods of performance from December 2021 through January 2023. The drug products will support the FDA's clinical, regulatory science, research, and compliance activities, including studies related to the Generic Drug User Fee Amendments program.

The original solicitation sought sources of currently marketed drug products for FDA research studies, with responses due in August 2020. WEP Clinical was awarded the indefinite delivery contract and subsequent delivery orders to provide the requested pharmaceuticals.

Generated 1/5/24, 12:23 AM